Lexaria's Technology Proven to Deliver Oral THC More Effectively

IBN Announces Latest Episode of Stock2Me Podcast Featuring Lexaria Bioscience Corp. Chairman & CEO Chris Bunka

DehydraTECH(TM) Nicotine Pouches Could Make Smoking Obsolete

Lexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding Results

Lexaria to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Lexaria Begins Investigational New Drug (IND) Enabling Program for DehydraTECH-CBD for Hypertension

Lexaria's Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory Period

Winning Formulation; Lexaria Takes Strategic Aim at High Value Hypertension and Antiviral Therapeutics Markets with Robust Drug Delivery Technology

Lexaria's DehydraTECH-CBD Lowers Blood Pressure

DehydraTECH-Enabled Consumer Products Now Available in Over 7,000 Stores

Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2

Lexaria Receives US$3,817,643 From Warrant Exercises

Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy

Lexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3

Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada's National Research Council

Lexaria Receives Patent Protection in Japan

Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets

Lexaria Announces 2021 Annual Meeting Results

Virtual Conference for Life Sciences Companies Broadcast Live June 24th, 2021

Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM)

Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs

Lexaria Provides Progress Report on Six R&D Programs

Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1

Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus

Lexaria's Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever

Lexaria Strengthens Its International Patent Portfolio to 19 Patents Granted

Lexaria's Antiviral Drug Evaluation Program Progressing

Rapid Progress in Hypertension Studies by Lexaria

Lexaria to Present and Meet with Investors One-on-One at the 33rd Annual Virtual ROTH Conference on March 15-17, 2021

Lexaria Enters Investor Relations Agreement

Lexaria Expands R&D Program to Address US$28 Billion Hypertension Market with Addition of Two Human Clinical Studies